pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › EXEL

EXEL PDUFA Date: XL092 with atezolizumab

FDA decision (PDUFA) target 2026-12-03 · Exelixis Inc. · Colorectal Cancer (CRC)

EXEL run-up into the PDUFA (last ~120 days)

$53.5$40.74
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-03
Drug / candidateXL092 with atezolizumab
IndicationColorectal Cancer (CRC)
CompanyExelixis Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT05425940 · nan

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the EXEL PDUFA date?
The FDA PDUFA target date for EXEL (Exelixis Inc.) is 2026-12-03 for XL092 with atezolizumab. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is EXEL's drug XL092 with atezolizumab?
XL092 with atezolizumab is Exelixis Inc.'s candidate under FDA review for Colorectal Cancer (CRC).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.